CPT 11

CPT-11

CPT-11, also known as Irinotecan, is a chemotherapy drug used primarily in the treatment of colorectal cancer. It is a type of topoisomerase inhibitor that works by interfering with the DNA replication process in cancer cells, ultimately leading to cell death.

Mechanism of Action

CPT-11 is a prodrug that is converted in the body to its active form, SN-38. SN-38 inhibits the enzyme topoisomerase I, which is essential for DNA replication and transcription. By inhibiting this enzyme, CPT-11 causes DNA damage and prevents cancer cells from proliferating.

Clinical Use

CPT-11 is commonly used in combination with other chemotherapy agents such as 5-fluorouracil and leucovorin in the treatment of metastatic colorectal cancer. It is also being studied for its effectiveness in treating other types of cancer, including lung cancer, ovarian cancer, and pancreatic cancer.

Side Effects

The use of CPT-11 can lead to several side effects, including:

• Diarrhea
• Nausea
• Vomiting
• Neutropenia
• Alopecia

Administration

CPT-11 is typically administered intravenously. The dosage and schedule depend on the specific treatment regimen and the patient's overall health.

History

CPT-11 was first approved by the Food and Drug Administration (FDA) in 1996 for the treatment of colorectal cancer. Since then, it has become a standard part of chemotherapy regimens for this type of cancer.

Related Pages

• Colorectal cancer
• Topoisomerase inhibitor
• Chemotherapy
• DNA replication
• Prodrug
• 5-fluorouracil
• Leucovorin